Extended Underperformance Against Benchmarks
Lincoln Pharmaceuticals has been struggling to maintain momentum relative to the Sensex and its sector peers. Over the past week, the stock has declined by 4.76%, significantly underperforming the Sensex’s modest 0.52% fall. The one-month performance is even more stark, with the stock shedding 9.78% while the Sensex gained 1.13%. Year-to-date, the stock has plunged 40.23%, contrasting sharply with the Sensex’s 8.55% rise. Over the last year, Lincoln Pharma’s shares have halved, falling 50.02%, whereas the Sensex has managed a 4.04% gain. These figures underscore a persistent weakness in the stock’s price action, signalling challenges that have yet to be resolved.
Technical Indicators and Price Levels Signal Continued...
Read More












